ID   SiHa/cDDP
AC   CVCL_K031
DR   CCRID; 4201PAT-CCTCC00271
DR   Wikidata; Q54953473
RX   Patent=CN101503674B;
RX   PubMed=22650020;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200903.
CC   Population: Japanese.
CC   Characteristics: Contains a complete HPV16 genome with a disruption of the E2 region and a small deletion (from parent cell line).
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Transformant: NCBI_TaxID; 333760; Human papillomavirus type 16 (HPV16).
CC   Derived from sampling site: Uterus; cervix.
DI   NCIt; C27676; Human papillomavirus-related cervical squamous cell carcinoma
DI   ORDO; Orphanet_213767; Squamous cell carcinoma of the cervix uteri
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0032 ! SiHa
SX   Female
AG   55Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 23-09-21; Version: 15
RX   Patent=CN101503674B;
RA   Liu S.-L., Wang H., Chen X.-L.;
RT   "Cervical cancer multidrug resistance cell strain established by
RT   cisplatin induction.";
RL   Patent number CN101503674B, 01-Jun-2011.
RX   PubMed=22650020;
RA   Chen X.-L., Wang H., Zhang X.-M., Liu H.-Q., Liu S.-L.;
RT   "Establishment of a cisplatin-resistant human cervical cancer cell
RT   line.";
RL   Sichuan Da Xue Xue Bao Yi Xue Ban 43:151-155(2012).